Cover Image
市場調查報告書

Zydus Cadila Healthcare Limited - 產品平台分析

Zydus Cadila Healthcare Limited - Product Pipeline Review - 2015

出版商 Global Markets Direct 商品編碼 224567
出版日期 內容資訊 英文 86 Pages
訂單完成後即時交付
價格
Back to Top
Zydus Cadila Healthcare Limited - 產品平台分析 Zydus Cadila Healthcare Limited - Product Pipeline Review - 2015
出版日期: 2015年09月30日 內容資訊: 英文 86 Pages
簡介

Zydus Cadila Healthcare Limited是在醫藥品有效成分(API)、製劑、藥用化妝品、動物藥等產品群所組成的廣幅業務上從開發到銷售一手包辦的全球性製藥公司。例如配合腸胃、心血管、婦產科系疾病、呼吸系統、疼痛管理、中樞神經系統、抗感染疾病、癌症、神經症、皮膚病、腎臟病相關疾病等各種治療用產品。

本報告提供Zydus Cadila Healthcare Limited的治療藥開發平台現狀及各開發階段比較分析,為您彙整藥物標的,作用機制,給藥途徑,各分子類型的治療藥評估,最新的企業新聞和發表,後期階段及中止的計劃等相關資訊。

Zydus Cadila Healthcare Limited的基本資料

Zydus Cadila Healthcare Limited概要

  • 主要資訊
  • 企業資料

Zydus Cadila Healthcare Limited:R&D概要

  • 主要的治療範圍

Zydus Cadila Healthcare Limited:開發平台的檢討

  • 各開發階段的開發中產品
  • 單劑產品
  • 合作夥伴產品
    • 合作夥伴產品/聯合治療模式

Zydus Cadila Healthcare Limited:開發中產品概況

  • 最後階段的開發中產品
    • 第三階段的產品/聯合治療模式
  • 臨床實驗階段的開發中產品
    • 第二階段的產品/聯合治療模式
    • 第一階段的產品/聯合治療模式
  • 初期階段產品開發中產品
    • IND/CTA Filed Products/Combination Treatment Modalities
    • 前臨床階段的產品/聯合治療模式
    • 藥物研發中的產品/聯合治療模式

Zydus Cadila Healthcare Limited:開發階段不明的開發中產品

  • 開發階段不明的產品/聯合治療模式

Zydus Cadila Healthcare Limited:藥物簡介

  • interferon beta-1b
  • saroglitazar
  • Vaccine for Live Measles, Mumps and Rubella
  • ZYH-7
  • ZYOG-1
  • PEG-EPO
  • Rabimabs Vaccine
  • Diptheria Tetanus Pertussis And Haemophilus Type B Conjugate Vaccine
  • Haemophilus Influenzae Type B Conjugated Vaccine
  • Live Attenuated Vaccine for Mumps
  • Live Attenuated Vaccine for Rubella
  • rituximab biosimilar
  • Tetanus Vaccine
  • Toxoid Vaccine for Diptheria and Tetanus
  • Vaccine for Diptheria, Tetanus and Pertussis
  • ZYD-1
  • ZYDPLA-1
  • ZYG-19
  • ZYGK-1
  • ZYPH-0907
  • ZYT-1
  • MAb-3
  • MAb-4
  • Biosimilar 4 for Acute Myocardial Infarction and Infertility
  • Drug for Atherosclerotic Plaque
  • ZYGL-241
  • Biosimilar 1 for Nephrology
  • Biosimilar 2 for Diabetes and Rheumatoid Arthritis
  • Biosimilar 3 for Rheumatoid Arthritis and Acute Myocardial Infarction
  • Biosimilar 5 for Infertility
  • Biosimilar 6 for Infertility
  • Biosimilar 7 for Infertility and Oncology
  • MAB-6
  • MAb-1
  • MAb-2

Zydus Cadila Healthcare Limited:開發平台分析

  • 標的別
  • 各給藥途徑
  • 各分子類型
  • 各作用機制

Zydus Cadila Healthcare Limited:最近的開發平台趨勢

Zydus Cadila Healthcare Limited:暫停中的計劃

Zydus Cadila Healthcare Limited:企業發表

Zydus Cadila Healthcare Limited:總公司和子公司的所在地

附錄

圖表一覽

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC07627CDB

Summary

Global Markets Direct's, 'Zydus Cadila Healthcare Limited - Product Pipeline Review - 2015', provides an overview of the Zydus Cadila Healthcare Limited's pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Zydus Cadila Healthcare Limited's, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides brief overview of Zydus Cadila Healthcare Limited including business description, key information and facts, and its locations and subsidiaries
  • The report reviews current pipeline of Zydus Cadila Healthcare Limited's human therapeutic division and enlists all their major and minor projects
  • The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones
  • Special feature on out-licensed and partnered product portfolio
  • The report summarizes all the dormant and discontinued pipeline projects
  • Latest company statement
  • Latest news and deals relating to the Zydus Cadila Healthcare Limited's pipeline products

Reasons to buy

  • Evaluate Zydus Cadila Healthcare Limited's strategic position with total access to detailed information on its product pipeline
  • Assess the growth potential of Zydus Cadila Healthcare Limited in its therapy areas of focus
  • Identify new drug targets and therapeutic classes in the Zydus Cadila Healthcare Limited's R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
  • Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
  • Develop strategic initiatives by understanding the focus areas of Zydus Cadila Healthcare Limited and exploit collaboration and partnership opportunities
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Plan mergers and acquisitions effectively by identifying the most promising pipeline of Zydus Cadila Healthcare Limited
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Explore the dormant and discontinued projects of Zydus Cadila Healthcare Limited and identify potential opportunities in those areas
  • Avoid Intellectual Property Rights related issues

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Zydus Cadila Healthcare Limited Snapshot
    • Zydus Cadila Healthcare Limited Overview
    • Key Information
    • Key Facts
  • Zydus Cadila Healthcare Limited - Research and Development Overview
    • Key Therapeutic Areas
  • Zydus Cadila Healthcare Limited - Pipeline Review
    • Pipeline Products by Stage of Development
    • Pipeline Products - Monotherapy
    • Pipeline Products - Combination Treatment Modalities
    • Pipeline Products - Partnered Products
      • Partnered Products/Combination Treatment Modalities
  • Zydus Cadila Healthcare Limited - Pipeline Products Glance
    • Zydus Cadila Healthcare Limited - Late Stage Pipeline Products
      • Pre-Registration Products/Combination Treatment Modalities
      • Phase III Products/Combination Treatment Modalities
    • Zydus Cadila Healthcare Limited - Clinical Stage Pipeline Products
      • Phase II Products/Combination Treatment Modalities
      • Phase I Products/Combination Treatment Modalities
    • Zydus Cadila Healthcare Limited - Early Stage Pipeline Products
      • IND/CTA Filed Products/Combination Treatment Modalities
      • Preclinical Products/Combination Treatment Modalities
      • Discovery Products/Combination Treatment Modalities
    • Zydus Cadila Healthcare Limited - Unknown Stage Pipeline Products
      • Unknown Products/Combination Treatment Modalities
  • Zydus Cadila Healthcare Limited - Drug Profiles
    • interferon beta-1b
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • MAb-1
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • measles vaccine
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • saroglitazar
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • tetanus vaccine
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • measles + mumps + rubella vaccine
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • ZYH-7
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • PEG-EPO
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Rabimabs
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • leishmaniasis vaccine
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • rituximab biosimilar
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • ZYAN-1
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • ZYDPLA-1
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • ZYG-19
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • ZYGK-1
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • ZYT-1
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Biosimilar 4 for Acute Myocardial Infarction, Infertility and Thrombosis
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Biosimilar 1 for Nephrology and Oncology
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Biosimilar 2 for Diabetes and Rheumatoid Arthritis
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Biosimilar 3 for Rheumatoid Arthritis, Acute Myocardial Infarction and Inflammation
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Biosimilar 5 for Infertility
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Biosimilar 6 for Infertility
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Biosimilar 7 for Infertility and Oncology
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Biosimilar 8 for Oncology
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Biosimilar for Immunology
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • diphtheria + tetanus + pertussis (whole-cell) + haemophilus influenzae [serotype B] vaccine
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • diphtheria + tetanus + pertussis (whole-cell) vaccine
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • diphtheria + tetanus vaccine
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • haemophilus influenzae [serotype B] vaccine
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • hepatitis A vaccine
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • hepatitis B vaccine
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • hepatitis E vaccine
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • influenza [strains A/H1N1 + A/H3N2 + B/Victoria + B/Yamagata] (tetravalent, split virion) vaccine
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • influenza [strains A/H1N1 + A/H3N2 + B/Yamagata] (trivalent, split virion) vaccine
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Japanese encephalitis vaccine
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • MAb-6
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • MAb-7
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • MAb-8
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • malaria vaccine
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Vaccine for Cervical Cancer and Genital Warts
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • typhoid vaccine
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • MAb-2
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • MAb-3
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • MAb-4
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • Zydus Cadila Healthcare Limited - Pipeline Analysis
    • Zydus Cadila Healthcare Limited - Pipeline Products by Target
    • Zydus Cadila Healthcare Limited - Pipeline Products by Route of Administration
    • Zydus Cadila Healthcare Limited - Pipeline Products by Molecule Type
    • Zydus Cadila Healthcare Limited - Pipeline Products by Mechanism of Action
  • Zydus Cadila Healthcare Limited - Recent Pipeline Updates
  • Zydus Cadila Healthcare Limited - Dormant Projects
  • Zydus Cadila Healthcare Limited - Company Statement
  • Zydus Cadila Healthcare Limited - Locations And Subsidiaries
    • Head Office
    • Other Locations & Subsidiaries
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Zydus Cadila Healthcare Limited, Key Information
  • Zydus Cadila Healthcare Limited, Key Facts
  • Zydus Cadila Healthcare Limited - Pipeline by Indication, 2015
  • Zydus Cadila Healthcare Limited - Pipeline by Stage of Development, 2015
  • Zydus Cadila Healthcare Limited - Monotherapy Products in Pipeline, 2015
  • Zydus Cadila Healthcare Limited - Combination Treatment Modalities in Pipeline, 2015
  • Zydus Cadila Healthcare Limited - Partnered Products in Pipeline, 2015
  • Zydus Cadila Healthcare Limited - Partnered Products/ Combination Treatment Modalities, 2015
  • Zydus Cadila Healthcare Limited - Pre-Registration, 2015
  • Zydus Cadila Healthcare Limited - Phase III, 2015
  • Zydus Cadila Healthcare Limited - Phase II, 2015
  • Zydus Cadila Healthcare Limited - Phase I, 2015
  • Zydus Cadila Healthcare Limited - IND/CTA Filed, 2015
  • Zydus Cadila Healthcare Limited - Preclinical, 2015
  • Zydus Cadila Healthcare Limited - Discovery, 2015
  • Zydus Cadila Healthcare Limited - Unknown, 2015
  • Zydus Cadila Healthcare Limited - Pipeline by Target, 2015
  • Zydus Cadila Healthcare Limited - Pipeline by Route of Administration, 2015
  • Zydus Cadila Healthcare Limited - Pipeline by Molecule Type, 2015
  • Zydus Cadila Healthcare Limited - Pipeline Products by Mechanism of Action, 2015
  • Zydus Cadila Healthcare Limited - Recent Pipeline Updates, 2015
  • Zydus Cadila Healthcare Limited - Dormant Developmental Projects,2015
  • Zydus Cadila Healthcare Limited, Subsidiaries

List of Figures

  • Zydus Cadila Healthcare Limited - Pipeline by Top 10 Indication, 2015
  • Zydus Cadila Healthcare Limited - Pipeline by Stage of Development, 2015
  • Zydus Cadila Healthcare Limited - Monotherapy Products in Pipeline, 2015
  • Zydus Cadila Healthcare Limited - Combination Treatment Modalities in Pipeline, 2015
  • Zydus Cadila Healthcare Limited - Pipeline by Top 10 Target, 2015
  • Zydus Cadila Healthcare Limited - Pipeline by Top 10 Route of Administration, 2015
  • Zydus Cadila Healthcare Limited - Pipeline by Top 10 Molecule Type, 2015
  • Zydus Cadila Healthcare Limited - Pipeline Products by Top 10 Mechanism of Action, 2015
Back to Top